SDGR

22.93012.95%
GL

Gary L. Sender

Independent Director

Mr. Gary L. Sender is Independent Director of Apnimed, Inc. from October 2024. Mr. Sender has extensive financial leadership experience across the biopharmaceutical industry, including serving on the board of directors of several public and private biotechnology companies. Mr. Sender serves as Independent Director at Harmony Biosciences, LLC since September 2021. He has been Director of Elucida Oncology, Inc. since April 2021. He serves on the board of Gennao Bio. Mr. Sender served as Chief Financial Officer of Nabriva Therapeutics GmbH since May 2016 to March 2021. He serves as Independent Director at Harmony Biosciences Holdings, Inc. since August 2020. He also serves on the Board of Directors of Harmony BioSciences Inc. He has been Independent Director of iBio, Inc. since October 14, 2020 and served as Lead Independent Director since December 2021 until November 10, 2022. Mr. Sender was the Chief Financial Officer at Nabriva Therapeutics Plc since April 12, 2017 until March 12, 2021. Mr. Sender previously served as Chief Financial Officer of Nabriva Therapeutics Plc from May 2016 until the Redomiciliation. Prior to joining Nabriva Austria, he served as Chief Financial Officer and Executive Vice President at Synergy Pharmaceuticals from November 2015 to April 2016. Mr. Sender is an Independent Director of Schrödinger, Inc. since July 2019. Mr. Sender is responsible for leading Nabriva's financial strategy and operations. He served as the Chief Financial Officer and Executive Vice President at Synergy Pharmaceuticals, Inc. since November 16, 2015 until April 30, 2016. Mr. Sender has extensive financial leadership experience in the pharmaceutical and biopharmaceutical industries. From August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance supporting Shire plc's Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was Senior Vice President of Finance and Administration at Shire Plc from August 2009 to June 2015. He was responsible for financial management and support of all commercial areas of Shire Specialty Pharmaceutical and Rare Disease businesses, including the Gastroenterology Business Unit, with an emphasis on resource allocation, financial forecasting, business cases and mergers & acquisitions. He served as Vice President of Finance, Administration and Chief Financial Officer of Tengion Inc. from August 2004 to July 2009. Mr. Sender served as Vice President of Investor Relations at Aramark Corporation since January 23, 2003. Mr. Sender joined ARAMARK from Merck & Co., Inc., where he served as Vice President and Controller for Merck's U.S. pharmaceuticals business. During his career with Merck & Co., Inc., Mr. Sender also served as a Director of Investor Relations, Executive Director of Financial Evaluation and Analysis and Assistant Treasurer. Prior to his work at Merck & Co., Inc., Mr. Sender held positions at&T and RCA Corporation. He serves as Director of Nabriva Therapeutics GmbH (formerly known as Nabriva Therapeutics AG). He served as Director at Nabriva Therapeutics Plc. He holds B.S degree in Finance and Information Systems from Boston University. He received his master’s degree in Business Administration (MBA) with a concentration in Finance from Carnegie-Mellon University.

Positions